During the last decades, several risk factors for the recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) have been investigated. However, the impact of two important drivers of oncogenesis, namely the immunosuppression and the treatment of acute cellular rejection (ACR) have been marginally addressed. This study aimed at investigating the impact of ACR treatment on the incidence of tumor recurrence in a large European HCC-LT population.
Hepatocellular carcinoma recurrence after acute liver allograft rejection treatment. A multicenter European experience / Lai, Q.; Iesari, S.; Finkenstedt, A.; Hoppe-Lotichius, M.; Foguenne, M.; Lehner, K.; Otto, G.; Lerut, J.. - In: HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL. - ISSN 1499-3872. - 18:6(2019), pp. 517-524. [10.1016/j.hbpd.2019.05.006]
Hepatocellular carcinoma recurrence after acute liver allograft rejection treatment. A multicenter European experience
Lai Q.
;
2019
Abstract
During the last decades, several risk factors for the recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) have been investigated. However, the impact of two important drivers of oncogenesis, namely the immunosuppression and the treatment of acute cellular rejection (ACR) have been marginally addressed. This study aimed at investigating the impact of ACR treatment on the incidence of tumor recurrence in a large European HCC-LT population.| File | Dimensione | Formato | |
|---|---|---|---|
|
Lai_Hepatocellular-carcinoma-recurrence_2019.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
487.28 kB
Formato
Adobe PDF
|
487.28 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
